Pfizer wants a piece of the showdown with the world’s biggest medicine. The New York pharma giant — facing an activist investor, shedding multiple parts of … ...
The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC), securing itself a shot at challenging Merck & Co. for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback